. 2021 Nov 2;49(5):1584–1594. doi: 10.1007/s00259-021-05594-8

Table 2.

Univariate and multivariable analysis of potential predictive factors for overall survival (OS)

Variable	n (%)	OS (months)	Univariate analysis		Multivariable analysis
Variable	n (%)	Median (95% CI)	HR (95% CI)	p	HR (95% CI)	p
Overall	66 (100)	18.0 (14.6–21.4)	-	-	-	-
TLP response
PR	40 (60.6)	24.6 (15.4–33.8)
SD/PD	26 (39.4)	10.7 (0–21.8)	2.78 (1.46–5.30)	0.001	2.76 (1.45–5.26)	0.002
PSA response
PR	34 (51.5)	24.6 (15.5–33.7)
SD/PD	32 (48.5)	14.5 (9.6–19.4)	2.30 (1.23–4.30)	0.008	1.39 (0.52–3.69)	0.515
ALP^a
< 220 U/L	54 (81.8)	23.4 (16.4–30.4)
≥ 220 U/L	12 (18.2)	7.1 (0–15.5)	4.08 (1.90–8.76)	< 0.001	3.08 (1.38–6.87)	0.006
Performance status^a
ECOG < 2	48 (72.7)	23.4 (17.1–29.6)
ECOG ≥ 2	18 (27.3)	8.1 (0–17.0)	2.98 (1.53–5.79)	< 0.001	2.21 (1.10–4.43)	0.026
Visceral metastases^a
No	43 (65.2)	19.3 (8.7–29.9)
Yes	23 (34.8)	16.2 (8.9–23.4)	1.78 (0.96–3.32)	0.064	1.61 (0.84–3.08)	0.154
PSA^a
< 145 ng/mL	33 (50.0)	23.4 (15.6–31.1)
≥ 145 ng/mL	33 (50.0)	16.2 (12.2–20.1)	-	0.105	-	-
Age^a
< 65 years	17 (25.8)	16.8 (11.1–22.6)
≥ 65 years	49 (74.2)	19.3 (15.1–23.5)	-	0.473	-	-
Prior chemotherapy^a
No	19 (28.8)	23.7 (12.0–35.4)
Yes	47 (71.2)	16.9 (11.5–22.3)	-	0.570	-	-
Hemoglobin^a
≥ 13 g/dL	22 (33.3)	18.0 (12.5–23.5)
< 13 g/dL	44 (66.7)	16.9 (10.8–23.0)	-	0.566	-	-
TLP^a
< 5710 mL × SUV	33 (50.0)	19.4 (11.1–27.8)
≥ 5710 mL × SUV	33 (50.0)	16.9 (10.3–23.5)	-	0.312	-	-
Initial ¹⁷⁷Lu activity^b
> 14 GBq	33 (50.0)	16.8 (14.4–19.3)
≤ 14 GBq	33 (50.0)	23.7 (11.5–35.9)	-	0.474	-	-

CI, confidence interval; HR, hazard ratio; TLP, total lesion PSMA; PSA, prostate-specific antigen; ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group. ^aBaseline parameter. ^bCumulative activity of the first two [¹⁷⁷Lu]Lu-PSMA-617 RLT cycles. p-values printed in bold type are statistically significant at p < 0.05